About vaccines

In a population-based cohort study, William Whiteley and colleagues investigate the association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events in England. // 22.2.2022

The new study, published in the journal Cell Host and Microbe, also finds that the neutralization against Omicron remains robust at four months after the third dose of the BNT162b2 vaccine. // 22.2.2022

New research in nursing home residents found that a third dose of the Pfizer-BioNTech COVID-19 vaccine was effective for at least three months in protecting against the Delta and Omicron variant. While two doses of an mRNA COVID-19 vaccine showed poor neutralization to Omicron than Delta, a booster shot increased neutralizing antibody responses. // 22.2.2022

Researchers conducted a prospective cohort study to assess the level and durability of protection offered by two doses of COVID-19 vaccine against SARS-CoV-2 infection in participants with no history of a previous infection. // 18.2.2022

Researchers conducted a retrospective cohort study to assess the rate of SARS-CoV-2 reinfection in patients who had recovered from COVID-19. // 18.2.2022

Scientific Reports - mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants // 16.2.2022

The present study entailed assessments of both infected and uninfected SOTRs against the D614G-CoV2 baseline virus and eight other variants. // 17.2.2022

New study findings reveal that the level of afucosylated anti-spike antibodies increases transiently in infection-naïve individuals after the first COVID-19 vaccine dose. // 17.2.2022

Original Article from The New England Journal of Medicine — Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection // 16.2.2022

Researchers compare the incidence rate of reinfection in convalescent and unvaccinated people to that in recovered and single-dose vaccinated people. // 16.2.2022

In a recent study posted to the medRxiv* preprint server, researchers evaluated the cross-reactivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-triggered neutralization and fragment crystallizable (Fc) effector functions between coronavirus disease 2019 (COVID-19)-vaccinated and unvaccinated individuals in South Africa. // 16.2.2022

Background: There is insufficient evidence regarding the magnitude and durability of protection conferred by a combined effect of naturally acquired immunity after SARS-CoV-2 infection and vaccine-induced immunity. //15.2.2022

Background: Waning immunity and the surge of SARS-CoV-2 variants are responsible for breakthrough infections, i.e. infections in fully vaccinated individuals. Although the majority of vaccinated infected subjects reports mild or no symptoms, some others require hospitalization. The clinical and immunological features of vaccinated hospitalized COVID-19 patients are currently unknown. // 15.2.2022

Getting vaccinated for COVID-19 measurably improved the psychological well-being of participants in the Understanding Coronavirus in America study, a large longitudinal look at the impact of the pandemic on individuals in the United States. // 15.2.2022

Researchers from the US performed a retrospective analysis to estimate excess COVID-19-associated deaths in the unvaccinated population of the US. // 15.2.2022

In a recent study posted to the medRxiv* preprint server, a team of researchers from the United States estimated the benefits of scaling up coronavirus disease 2019 (COVID-19) vaccination in the low- and lower-middle-income countries (LIC/LMICs) amid the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant using economic and epidemiological models linearized with public data of COVID-19 vaccinations and deaths. // 15.2.2022

Nature - Germinal centre-driven maturation of B cell response to mRNA vaccination // 15.2.2022

In a recent study posted to the medRxiv* preprint server, researchers evaluated the efficacy and safety of the coronavirus disease 2019 (COVID-19) vaccines in young and elderly cohorts from Canada. // 14.2.2022

A new JAMA Network study describes the effects of maternal COVID-19 vaccination on pregnancy outcomes and infant health. // 14.2.2022

A new study investigated the various factors affecting the acceptance rate and trust in SARS-CoV-2 vaccines in countries with high rates of vaccination. // 14.2.2022

In a recent study, researchers demonstrated that COVID-19 symptoms varied between cases of SARS-CoV-2 Omicron and Delta variants of concern. // 14.2.2022

The SARS-CoV-2 Omicron variant largely escapes neutralizing antibodies elicited by vaccines or infection. However, whether Omicron triggers humoral responses that are cross-reactive to other variants of concern (VOCs) remains largely unknown. // 14.2.2022

A new study aimed to investigate the mechanism by which the third booster BNT162b2 dose impacts anti-S levels. // 14.2.2022

Researchers analyze suspected reactions in patients vaccinated with the first and/or second dose of SARS-CoV-2 vaccines. // 13.2.2022

Researchers assess the incidence of SARS-CoV-2 breakthrough cases and reinfections among unvaccinated and vaccinated individuals. // 13.2.2022

A recent study examined the clinical severity of the SARS-CoV-2 Alpha, Delta, and Omicron VOCs and compared vaccine effectiveness against each VOC. // 10.2.2022

A new study demonstrated that infection- and vaccine-induced protection induced by the primary COVID-19 vaccination was much reduced for the Omicron BA.1 infection compared to the Delta infection. // 10.2.2022

Importance: Despite widespread vaccination against COVID-19 in the United States, there are limited empirical data quantifying the public health impact in the population. // 9.2.2022 ”We estimated that 1,523,500 [95% prediction interval (976,800-2,230,800)] COVID-19 cases were averted and there was a 34% [95% prediction interval (25-43)] reduction in cases due to vaccination in the primary model. ”

Scientists have recently studied the duration of protection provided by mRNA-based COVID-19 vaccines against symptomatic omicron infection, and associated severity and mortality. // 9.2.2022

Researchers looked at the efficiency of COVID-19 vaccines in preventing infection, hospitalization, and death in the general population of Sweden over the first nine months following vaccination. // 9.2.2022